Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- momelotinib
- talimogene laherparepvec
Interactions between your drugs
talimogene laherparepvec momelotinib
Applies to: talimogene laherparepvec, momelotinib
CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.
MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Ojjaara
Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Inrebic
Inrebic is used to treat certain types of myelofibrosis (MF) in adults. It is an oral capsule taken ...
Fedratinib
Fedratinib is used for certain types of myelofibrosis (MF) in adults, relieving night sweats ...
Pacritinib
Pacritinib (brand name Vonjo) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.